Beneficial Effect of Mas Receptor Deficiency on Vascular Cognitive Impairment in the Presence of Angiotensin II Type 2 Receptor

Akinori Higaki, MD; Masaki Mogi, MD, PhD; Jun Iwanami, PhD; Li-Juan Min, MD, PhD; Hui-Yu Bai, MD; Bao-Shuai Shan, MD; Masayoshi Kukida, MD, PhD; Toshifumi Yamauchi, MD; Kana Tsukuda, BS; Harumi Kan-no, MS; Shuntaro Ikeda, MD, PhD; Jitsuo Higaki, MD, PhD; Masatsugu Horiuchi, MD, PhD

Background—The classical renin-angiotensin system is known as the angiotensin (Ang)-converting enzyme/Ang II/Ang type 1 receptor axis, which induces various organ damage including cognitive decline. The angiotensin-converting enzyme 2/Ang-(1-7)/Mas axis is known to exert antagonistic actions against the classical renin-angiotensin system axis in the cardiovascular system. However, its roles in the brain remain unclear. We examined possible roles of the angiotensin-converting enzyme 2/Ang-(1-7)/Mas axis in cognitive function, employing vascular cognitive impairment model mice.

Methods and Results—Male 10-week-old C57BL6 (wild-type mice, Mas1 knockout mice, Ang II type 2 receptor knockout mice, and Ang II type 2 receptor/Mas1 double knockout mice) were subjected to bilateral carotid artery stenosis (BCAS) surgery. Six weeks after treatment, they were subjected to cognitive tasks. Brain samples were used for histopathological analysis. Cognitive function was significantly impaired in wild-type and double knockout mice after BCAS. On the other hand, the cognitive function of Mas1 knockout mice was maintained in spite of the reduction of cerebral blood flow with BCAS. Total cell number in the dentate gyrus region was significantly reduced after BCAS in wild-type but not in Mas1 knockout mice. The number of doublecortin-positive cells in the subgranular zone was not significantly different between wild-type and Mas1 knockout mice. Ang-(1-7) administration did not improve cognitive function in all mice after BCAS surgery.

Conclusions—Lack of the Mas receptor may have a protective effect against chronic brain ischemia when the Ang II type 2 receptor exists. (J Am Heart Assoc. 2018;7:e008121. DOI: 10.1161/JAHA.117.008121.)

Key Words: angiotensin II • angiotensin II type 2 receptor • angiotensin receptor • angiotensin-(1-7) • Mas receptor • neurogenesis • neuroprotection • vascular cognitive impairment • vascular dementia

Dementia is becoming a serious health problem worldwide, yet the efficacy of current treatment is limited. One of the most important risk factors for dementia is hypertension, and some antihypertensive drugs are expected to reduce the prevalence of dementia.1,2 The classical renin-angiotensin system (RAS) is closely associated with the pathogenesis of hypertension and other cardiovascular disease, and we have reported that activation of the classical RAS causes deterioration of cognitive function.3

In contrast to the classical RAS, there are some organ-protective components, one of which is the angiotensin (Ang) type 2 (AT2) receptor. We previously reported that activation of the AT2 receptor improved learning and memory in a vascular dementia model.4 Recently, the angiotensin-converting enzyme 2 (ACE2)/Ang-(1-7)/Mas receptor axis has also aroused interest as another protective arm of RAS.5 It is known that the Mas receptor is highly expressed in the hippocampus and blood vessels in the brain.6 Since the hippocampus plays an important role in the formation of new memories, a relationship between cognitive function and this axis is suggested. Consistent with this concept, Hellner reported that Ang-(1–7) could increase long-term potentiation (LTP) in the hippocampus through its interaction with the Mas receptor.7

Ang-(1-7) is a main product of Ang II degradation by ACE2 and is known to be an endogenous ligand of the Mas receptor.

From the Departments of Molecular Cardiovascular Biology and Pharmacology (A.H., M.M., J.I., L.-J.M., H.-Y.B., B.-S.S., M.K., K.T., H.K.-n., M.H.), Cardiology, Pulmonology, Hypertension and Nephrology (A.H., M.K., S.I., J.H.), and Pediatrics (T.Y.), Graduate School of Medicine, Ehime University, Tohon, Ehime, Japan.

Accompanying Data S1, Tables S1 and S2, and Figures S1 and S2 are available at http://jaha.ahajournals.org/content/7/3/e008121/DC1/inline-supplementary-material-1.pdf

Correspondence to: Masaki Mogi, MD, PhD, Department of Molecular Cardiovascular Biology and Pharmacology, Graduate School of Medicine, Ehime University, Shitsukawa, Tohon, Ehime 791-0295, Japan. Email: mmogi@m.ehime-u.ac.jp

Received November 15, 2017; accepted December 18, 2017.

© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Ang-(1-7) is reported to increase cerebral blood flow (CBF) and reduce vascular resistance.8 We recently reported that ACE2 deficiency caused cognitive decline and Ang-(1-7) treatment prevented the worsening of cognitive function.9 However, the effect of Mas receptor deficiency on cognitive function is still unclear. In previous reports, Mas1 knockout (MasKO) mice showed impaired novel object cognition but no worsening of spatial memory. Interestingly, MasKO mice are reported to show a greater increase of LTP compared with wild-type (WT) mice.10,11

To highlight the role of this axis in cognitive function, we employed a disease model. Because of the vasoactive properties of Ang-(1-7), a vascular dementia model seems to be the most suitable way to investigate its role in cognitive function. Therefore, we decided to use a vascular dementia mouse model. Considering the possible interaction between RAS components, we conducted 2-step experiments. First, we evaluated the degree of cognitive decline after bilateral carotid artery stenosis (BCAS) in WT, MasKO, and Mas/AT2 receptor double knockout (DKO) mice to investigate the additional impact of the AT2 receptor on MasKO mice. After examining the results, we evaluated the effect of Ang-(1-7) administration on WT, MasKO, AT2 receptor knockout mice (AT2KO), and DKO mice.

Evaluation of Cognitive Function

The apparatus for the Y-maze test has 3 arms, 400 mm in length and 150 mm in height, each separated by an angle of 120° (Brain Science Idea Co, Ltd). Each mouse was placed in the center of the apparatus and allowed to explore the maze for 8 minutes. We manually recorded their arm choices. Any 3 consecutive choices of 3 different arms were counted as an alternation. Working memory was evaluated as the percentage of alternation in all arm choices. The total number of arm entries is considered an indicator of spontaneous locomotive
activity. Animals whose spontaneous locomotive activity was less than 10 were removed from analysis because working memory could not be evaluated properly. The MWM test was performed 6 weeks after BCAS surgery, as previously described. Mice were trained 5 times a day at 20-minute intervals for 5 consecutive days. In each trial, mice were given 120 seconds to find the platform. Swimming was video-recorded (AnyMaze, Stoelting Co), and latency, path length, swim speed, and cumulative distance from the platform were recorded. Mean swim latency for each day was evaluated and compared between groups.

Measurement of CBF

After the cognitive tasks, CBF was measured by laser speckle flowmetry (Omegazone laser speckle blood flow imager; Omegawave), which obtains high-resolution 2-dimensional images in seconds, as previously described. Mice were anesthetized with pentobarbital, and a midline incision was made in the scalp. Blood pressure (BP) was not affected by anesthesia. The skull was exposed and wet with saline. A 780-nm semiconductor laser illuminated the whole skull surface. Mean CBF on the skull surface was measured. Light intensity was accumulated in a charge-coupled device camera and transferred to a computer for analysis. Image pixels were analyzed to produce average perfusion values.

Real-Time Reverse Transcription–Polymerase Chain Reaction Method

Samples of hippocampus were frozen in liquid nitrogen and stored at −80°C until analysis. Total mRNA was extracted from brain samples after homogenization in Sepazol (Nacalai Tesque Inc). Real-time quantitative reverse-transcription polymerase chain reaction was performed with an SYBR green I kit (MJ Research, Inc). The polymerase chain reaction was performed with an SYBR 5′-ATGGAGCCATGAGGTCCAC-3′ (forward) and 5′-TGCGACTTCAACAGCAACTC-3′ (reverse) for GAPDH, 5′-AGTCGACACTCAAGCCTGTCT-3′ (forward) and 5′-AC TGTCCTTCTGTGCGAG-3′ (reverse) for angiotensin II type 1 receptor (AT1 receptor), 5′-CTGTGAGTGTCGATAGGT-3′ (forward) and 5′-CCGCACTACCATTCAACAATA-3′ (reverse) for AT2 receptor, 5′-AGAGGCACAAAGCCGACATGTGAT-3′ (forward) and 5′-AGTTTCCAGGGCTGTTGTC-3′ (forward) and 5′-TC TGTCCTGAGGCTCCTCA-3′ (reverse) for Mas1, 5′-CCACGTCAAGGGCTAAT-3′ (forward) and 5′-GCCAGACGACCTCAACTCA-3′ (reverse) for AT2 receptor, 5′-AGGCAGACAAAGCCGACATGTGAT-3′ (forward) and 5′-AGTTTCCAGGGCTGTTGTC-3′ (forward) and 5′-TC TGTCCTGAGGCTCCTCA-3′ (reverse) for Mas1, 5′-CCACGTCAAGGGCTAAT-3′ (forward) and 5′-GCCAGACGACCTCAACTCA-3′ (reverse) for AT2 receptor, 5′-AGGCAGACAAAGCCGACATGTGAT-3′ (forward) and 5′-AGTTTCCAGGGCTGTTGTC-3′ (forward) and 5′-TC TGTCCTGAGGCTCCTCA-3′ (reverse) for Mas1, 5′-CCACGTCAAGGGCTAAT-3′ (forward) and 5′-GCCAGACGACCTCAACTCA-3′ (reverse) for AT2 receptor, 5′-AGGCAGACAAAGCCGACATGTGAT-3′ (forward) and 5′-AGTTTCCAGGGCTGTTGTC-3′ (forward) and 5′-TC TGTCCTGAGGCTCCTCA-3′ (reverse) for Mas1.

Statistical Analysis

All values are expressed as mean±SEM. Comparisons between 2 groups were analyzed using Levene test for equal variances then Student (equal variances) or Welch (unequal variances) t tests as appropriate. Comparisons between ≥3 groups were analyzed using ANOVA, then, when significant differences were indicated, were followed by post hoc pairwise comparisons using Tukey-Kramer method to adjust for multiple hypothesis testing. For each experiment, the overall significance threshold was set to 0.05. Statcel 3 (OMS
Inc) add-in software for Microsoft Excel was used for statistical analysis.

Results

Body Weight, Brain Weight, and BP

Table S1 shows the characteristics of the mice. Sham-operated MasKO mice showed significantly heavier body weight compared with WT-sham, but there was no significant difference in brain/body weight ratio. Systolic BP in AT2KO-BCAS and DKO-BCAS mice were significantly higher than those in sham mice. Multiple comparison analysis showed no significant difference among all BCAS groups.

Change in CBF After BCAS

Figure 1 shows mean CBF measured by laser speckle flowmetry. CBF significantly decreased after BCAS compared with that in sham mice in each group, although no significant intergroup difference was seen among the BCAS-treated groups. Time-course analysis of CBF also showed no significant difference in each group (Figure S1). This means that DKO mice did not show a further decrease in CBF compared with MaskKO mice.

Cognitive Function

We evaluated working memory and spontaneous locomotive activity with the Y-maze test (Figure 2A and 2B). The total number of arm entries was significantly lower in MasKO-sham mice than WT-sham and DKO-sham mice. WT-BCAS mice showed significantly lower working memory than WT-sham mice. On the other hand, MasKO mice did not show significant deterioration after BCAS surgery. A slight reduction in alternation was also observed in the MasKO mice, but the effect did not reach statistical significance (P=0.79). AT2KO mice also exhibited lower spontaneous locomotive activity than DKO-sham mice. However, there was no significant difference among BCAS-treated mouse groups. Working memory in DKO mice tended to decrease after BCAS (P=0.07). Multiple comparison analysis did not show a significant difference among all groups with BCAS. To avoid visual problems after BCAS operation, we performed visible platform task. No significant difference was observed in the BCAS-induced impairment of cognition in each mouse.

Figure 1. Cerebral blood flow (CBF) changes after bilateral common carotid artery stenosis (BCAS) surgery. A, Representative CBF images of groups assessed by laser speckle flowmetry 6 weeks after surgery. B, Quantitative analysis of CBF indicated as arbitrary unit determined by Doppler method. CBF decreased significantly after BCAS in each group (n=7–22 for each group). *P<0.01 vs sham. †P<0.05 vs sham. AT2KO indicates angiotensin II type 2 receptor knockout mice; DKO, Mas/angiotensin II type 2 receptor double knockout mice; MasKO, Mas receptor knockout mice; WT, wild-type mice.

DOI: 10.1161/JAHA.117.008121
We also evaluated spatial memory with the MWM test (Figure 2C). WT mice showed significant deterioration of cognitive function after BCAS. However, MasKO mice did not show a significant decline after BCAS. Compared with other groups, AT2KO and DKO mice showed significantly lower performance in the MWM test even without BCAS treatment, and still showed worse cognitive function than WT-BCAS mice. There was no significant deference between AT2KO and DKO mice with BCAS treatment.

**mRNA Expression**

We measured mRNA expression of AT1R, AT2R, Mas1R, and inflammatory cytokines in the hippocampus with real-time quantitative reverse-transcription polymerase chain reaction. As shown in Figure 3, there was no significant difference in AT1 receptor and AT2 receptor expression among the groups. The expression of Mas1 receptor was significantly higher in AT2KO-BCAS than WT-BCAS mice. There was also no significant difference in the expression of brain-derived neurotrophic factor and inflammatory cytokines (interleukin 6 and monocyte chemotactic protein-1).

**Cell Number and Proliferation in Dentate Gyrus**

We assessed morphological changes with hematoxylin-eosin staining. The area ratio of the hippocampus did not significantly differ from that in samples with BCAS (data not shown).
There was no significant difference in the cell number in the cornu ammonis area 1 among all groups. However, the cell number in DKO mice only showed the tendency to decrease after BCAS treatment in the area. On the other hand, WT-BCAS mice showed significantly reduced cell number in dentate gyrus area compared with sham mice. MasKO mice and DKO mice did not show significant changes after BCAS treatment in the dentate gyrus area (Figure 4A and 4B). There was no significant difference in the number of pyknotic cells between WT and MasKO mice (data not shown).

To estimate the amount of neurogenesis, we counted the number of DCX-positive cells in the subgranular zone. The number of DCX-positive cells per area did not significantly change after BCAS treatment in all mouse groups, but the cell number in DKO mice tended to decrease in the BCAS-treated group ($P = 0.09$). Although the number of DCX-positive cells per area was the highest in DKO-sham mice, this did not reach statistical significance with 1-way ANOVA ($P = 0.07$) (Figure 4C).

**Effect of Ang-(1-7) on Cognitive Function**

We administered Ang-(1-7) intraperitoneally using an osmotic minipump at a dose of 0.5 mg/kg per day to assess its effect on the vascular cognitive impairment model. Ang-(1-7) administration did not significantly affect body weight, brain weight, or brain/body ratio. The BP in AT$_2$KO was significantly lower with Ang-(1-7)–treated mice than with vehicle mice. However, there was no significant intergroup difference (Table S2).
CBF did not significantly change after Ang-(1-7) administration in all groups, and multiple comparison analysis showed no significant intergroup difference (data not shown). We assessed the effect of Ang-(1-7) administration on cognitive function with BCAS-treated mice. There was no significant difference between Ang-(1-7)–administered mice and vehicle-treated mice in all groups with MWM test. The reason we did not observe any preventive effects of Ang-(1-7) on cognitive function is the duration of Ang-(1-7) treatment. We administered Ang-(1-7) from 2 weeks after BCAS operation to avoid inflammatory effects of pump replacement because we used a minipump for 4 weeks of treatment. Further analysis is necessary to confirm the effect of Ang-(1-7) treatment (Figure 5).

Discussion

This study showed that deficiency of the Mas receptor did not worsen cognitive function in vascular dementia model mice. Moreover, the degree of deterioration in cognitive function was significantly smaller than that in WT mice.

In general, the ACE2/Ang-(1-7)/Mas axis is believed to be an organ-protective axis and is expected to provide a beneficial effect on cognitive function in the brain. However, the role of the Mas receptor in the central nervous system is not clearly understood and there remains controversy concerning its effect on memory and other cognitive function. The total number of arm entries was significantly lower in MasKO-sham mice than WT-sham and DKO-sham mice. AT2KO mice also exhibited lower spontaneous locomotive activity than DKO-sham mice. However, there was no significant difference among BCAS-treated mouse groups. Spontaneous locomotive activity is associated with the function of amygdala and could be influenced by emotional conditions such as fear and anxiety. MasKO mice were reported to present increased anxiety and contextual fear memory.11,15 Similarly, anxiety-like behavior in AT2KO mice has also been reported.16 We believe these behavioral phenotypes could affect the spontaneous activity, but do not have enough evidence to understand the mechanism. As the baseline performance is different in AT2KO and DKO mice, we should take this into account when interpreting the results of behavioral tests. In 1998, Walther et al11 reported that MasKO mice show increased LTP, and reasonably asserted that the Mas receptor is a memory suppressor. Yet, they failed to show a difference in cognitive function between WT and MasKO mice with the MWM test. Later, their team found that Ang-(1-7) enhanced LTP in the hippocampus in WT mice but not in MasKO mice.7 We assumed that the function of the ACE2/Ang-(1-7)/Mas axis becomes more obvious in pathological conditions such as a dementia model. Because Ang-(1-7) is reported to be formed in vascular endothelial cells and has the potential to increase CBF,17 we
Mas De • increase in the number of DCX-positive cells in the dentate CBF is reported to impair neuronal function,18 but MasKO among all groups (data not shown). Long-term reduction in

DOI: 10.1161/JAHA.117.008121

Figure 5. Effect of Ang-(1-7) on cerebral blood flow and cognitive function. Effect of Ang-(1-7) was estimated with the Morris water maze test. All mice underwent bilateral common carotid artery stenosis (BCAS) surgery before drug administration. The mean escape latency did not significantly change between sham mice and BCAS-treated mice among all groups. (n=8–14 for each group). *P<0.05 vs Mas receptor knockout mice (MasKO–BCAS with vehicle. †P<0.05 vs MasKO-BCAS with Ang-(1-7). AT2KO indicates angiotensin II type 2 receptor knockout mice; DKO, Mas/angiotensin II type 2 receptor double knockout mice; WT, wild-type mice.

decided to use a vascular dementia mouse model to assess the effects.

In this study, mean CBF was significantly reduced in MasKO mice with BCAS, and there was no significant difference to that in WT-BCAS mice. We assessed the CBF changes at 4 different timepoints after BCAS treatment (just after or 1, 2, or 4 weeks after the surgery). Overall, there was no significant difference in the percentile changes in CBF among all groups (data not shown). Long-term reduction in CBF is reported to impair neuronal function,18 but MasKO mice did not show inferior performance in both the Y-maze test and the MWM test, in contrast to WT mice. In spite of the cerebral hypoperfusion, we could not detect significant changes in histological analysis in MasKO mice. We also did not observe a significant difference in mRNA expression of inflammatory cytokines, which are believed to be related to cognitive function. Moreover, we did not detect changes of gliosis evaluated by glial fibrillary acidic protein immunohistochemistry among WT, MasKO, and DKO-BCAS mice in the brain after 6 weeks of BCAS operation (data not shown). Kluver-Barrera staining also did not show a significant difference in the severity of white matter lesions as evaluated in a previous report among BCAS-treated groups (Figure S2).14

To investigate the reason for this resilience to ischemia, we focused on the amount of neurogenesis in the hippocampus. Freund et al19 reported that Mas deficiency resulted in an increase in the number of DCX-positive cells in the dentate gyrus, and discussed the possibility that increased neurogenesis leads to enhanced LTP in MasKO mice. However, no significant difference was seen in the number of DCX-positive cells between WT and MasKO mice. Moreover, DCX-positive cells tended to decrease in MasKO after BCAS. The discordance with the previous report might be attributable to the different scanned area (whole brain or single slice) and relatively smaller sample size of MasKO-sham. In any case, neurogenesis does not seem to fully explain the maintenance of cognitive function in MasKO.

Another conceivable mechanism is that deletion of the Mas receptor altered the balance of other RAS components and provided a beneficial effect indirectly. In this study, mRNA expression of the AT1 and AT2 receptors was not significantly affected by deficiency of the Mas receptor. On the other hand, the expression of Mas receptor was significantly higher in AT2KO mice than in WT mice after BCAS treatment. So, we assumed that unbound Ang-(1-7), which was caused by Mas deletion, could act as a ligand for other receptors. Generally, Ang-(1-7) has been believed to be a specific ligand for the Mas receptor. However, there is a report that shows it has relatively higher binding affinity to the AT2 receptor rather than the AT1 receptor.20 Leonhardt et al21 reported the functional interaction between AT2 and Mas receptor showing the evidence of heterodimerization with fluorescence resonance energy transfer technology. They also reported their functional dependence in mouse astrocytes. According to the report, the lack of one receptor impairs the other receptor’s response to its ligand. We previously reported that Ang-(1-7) administration reduced neointimal formation in injured arteries, through both Mas and AT2 receptor stimulation.22 In addition, we previously reported that direct AT2 receptor stimulation prevents cognitive decline after BCAS.4 Accordingly, we assumed that unbound Ang-(1-7) could activate the AT2 receptor and maintain cognitive function in MasKO mice. To test this hypothesis, we administered Ang-(1-7) to WT, MasKO, AT2KO, and DKO mice. As a result, Ang-(1-7) did not affect BP or CBF (please see Supplemental Table S2). A statistically significant difference between MasKO and DKO mice with Ang-(1-7) administration was only seen in the MWM test. This means that the combination of activated AT2 receptor and Mas receptor deficiency could be an effective way to preserve spatial learning.

Angiotensin-converting enzyme inhibition works not only on the reduced conversion of Ang I to Ang II, which blocks AT1 receptor signaling, but also on the increased conversion of Ang-(1-9) to Ang-(1-7), enhancing organ-protective effects. Therefore, it has been suggested that the vasoconstrictive/proliferative actions by Ang II of Ang-(1-7) depends on the angiotensin-converting enzyme/ACE2 ratio balance.5 WT-BCAS mice administered perindopril at the dose of 1 mg/kg per day in drinking water after 2 weeks from BCAS treatment showed better cognitive function than those administered
normal drinking water (data not shown). Therefore, angioten-
sin-converting enzyme inhibition may have potent or diverse
strengths related to enzyme inhibition or AT1 receptor
blockade.

Taking all of these results into account, we conclude that
Mas receptor deficiency has a beneficial effect on vascular
cognitive impairment, and this protective effect is only
brought about under the existence of the AT2 receptor. Since
the mechanistic insights remain limited, focusing more on
dose-response relationships, sex differences, pretreatment
versus posttreatment, and use of aged mice could help us
understand the detailed mechanisms in future studies.
However, we believe this study creates a stir in the
comprehension of the ACE2/Ang-(1-7)/Mas axis in the
central nervous system.

Conclusions
We demonstrated that Mas receptor deficiency brought about
a beneficial effect on cognitive function in a vascular cognitive
impairment mouse model in which the AT2 receptor was
preserved. This result could enable us to think about brain
protection from another viewpoint.

Acknowledgments
We thank Takeshi Kiyoi, Hirotomo Nakaoka, and Yuta Yanagihara for
their devoted technical support of this work.

Sources of Funding
This study was supported by JSPS KAKENHI (grant number
25293310 to Horiuchi, 25462220 to Mogi, 15K19974 to
Iwanami, and 26860567 to Min) and research grants from
pharmaceutical companies Astellas Pharma Inc, Bayer
Yakuhin, Ltd, Daiichi-Sankyo Pharmaceutical Co, Ltd, Nippon
Boehringer Ingelheim Co, Ltd, Novartis Pharma K. K., Shionogi
& Co Ltd, and Takeda Pharmaceutical Co, Ltd. The funders
had no role in the study design, data collection and analysis,
decision to publish, or preparation of the article.

Disclosures
None.

References
1. Czuriga-Kovacs KR, Czuriga D, Csiba L. Influence of hypertension, alone and in
combination with other vascular risk factors on cognition. CNS Neurol Disord
system blockade use and risks of cognitive decline and dementia: a meta-
Higaki J, Horiuchi M. Continuous activation of renin-angiotensin system
impairs cognitive function in renin/angiotensinogen transgenic mice. Hyper-
HY, Shen BS, Kukida M, Horiuchi M. Direct angiotensin II type 2 receptor
5. Santos RA, Ferreira AJ, Simes OASAC. Recent advances in the angiotensin-
converting enzyme 2-angiotensin-(1-7)/Mas axis. Exp Physiol. 2006;93:519–
527.
6. Freund M, Walthter T, von Bohlen und Halbach O. Immunohistochemical
localization of the angiotensin-(1-7) receptor Mas in the murine forebrain. Cell
in the hippocampus through the G-protein-coupled receptor Mas. Mol Cell
8. Sampalo WO, Nascimento AA, Santos RA. Systemic and regional hemody-
Kukida M, Chisaka T, Yamauchi T, Higaki A, Mogi M, Horiuchi M. Deficiency of
angiotensin-converting enzyme 2 causes deterioration of cognitive function.
10. Lazaroni TL, Raslan AG, Fontes WR, de Oliveira ML, Bader M, Alenina N,
Moraes MF, Dos Santos RA, Pereira GS. Angiotensin-(1-7)/Mas axis integrity
is required for the expression of object recognition memory. Neurobiol Learn
D, Bader M. Sustained long term potentiation and anxiety in mice lacking the
Horiuchi M. Sex-different effect of angiotensin II type 2 receptor on ischemic
nitric oxide and superoxide release from endothelial cells. Hypertension.
2001;37:72–76.
activation in a novel mouse model of chronic cerebral hyperperfusion. Stroke.
15. Lazaroni TL, Bastos CP, Moraes MF, Santos RA, Pereira GS. Angiotensin-(1-7)/
Mas axis modulates fear memory and extinction in mice. Neurobiol Learn
behavior in mice lacking the angiotensin II type-2 receptor. Brain Res.
17. Pena Silva RA, Chu Y, Miller JD, Mitchell II, Penninger JM, Faraci FM, Heistad
DD. Impact of ACE2 deficiency and oxidative stress on cerebrovascular
19. Freund M, Walthter T, von Bohlen Und Halbach O. Effects of the angiotensin-
(1-7) receptor Mas on cell proliferation and on the population of doublecortin
positive cells within the dentate gyrus and the piriform cortex. Eur
Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2
M, Multhaup G, Schulein R, Bader M, Santos RA, Unger T, Steckelings UM.
Evidence for heterodimerization and functional interaction of the angiotensin
22. Ohshima K, Mogi M, Nakaoka H, Iwanami J, Min LJ, Kanno H, Tsukuda K,
Chisaka T, Bai HY, Wang XL, Ogimoto A, Higaki J, Horiuchi M. Possible role of
angiotensin-converting enzyme 2 and activation of angiotensin II type 2
receptor by angiotensin-(1-7) in improvement of vascular remodeling by
SUPPLEMENTAL MATERIAL
Methods

Body weight, brain weight and blood pressure

Body weight and brain weight were measured at 16-week-old. Blood pressure was measured by the tail-cuff method with a blood pressure monitor (MK-2000ST NP-NIBP MONITOR, Muromachi Kikai Co., Ltd., Tokyo, Japan), before entering the cognitive tasks. Values were expressed as the mean of at least five measurements in each group.

Severity of the white matter lesion

Severity of the white matter lesion was evaluated with Klu¨ver-Barrera (KB) staining. Brain samples were embedded in paraffin and sliced into 5-μm-thick coronal sections. We evaluated the white matter changes in corpus callosum area adjacent to the lateral ventricle with KB staining. Samples were examined with an upright microscope (Axioskop 2, Carl Zeiss, Oberkochen, Germany) at x200 magnification.

Time-course analysis of CBF changes after BCAS surgery

Time-course of changes in cerebral blood flow (CBF) after BCAS surgery was measured by laser speckle flowmetry (Omegazone laser speckle blood flow imager; Omegawave,
Tokyo, Japan). CBFs were measured at the point of 0, 1, 2, 4 and 6 weeks after the BCAS and the percentage to the baseline was indicated in all mouse groups.

Statistical Analysis

All values are expressed as mean ± SEM. Comparisons between two groups were analyzed using Levene's test for equal variances then Students (equal variances) or Welch's (unequal variances) t-test as appropriate. Comparisons between three or more groups were analyzed using ANOVA then, when significant differences were indicated, were followed by post-hoc pairwise comparisons using Tukey-Kramer method to adjust for multiple hypothesis testing. For each experiment the overall significance threshold was set to 0.05. Statcel 3 (OMS Inc., Japan), add-in software for Microsoft Excel was used for statistical analysis.
**Table S1.** Body weight, brain weight and systolic blood pressure in each group.

<table>
<thead>
<tr>
<th>BCAS (+ / -)</th>
<th>Body weight (g)</th>
<th>Brain weight (g)</th>
<th>Brain/Body weight ratio(%)</th>
<th>Systolic blood pressure(mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT -</td>
<td>26.9 ± 0.4</td>
<td>0.45 ± 0.008</td>
<td>1.62 ± 0.03</td>
<td>105.3 ± 4.1</td>
</tr>
<tr>
<td>+</td>
<td>27.6 ± 0.4</td>
<td>0.44 ± 0.008</td>
<td>1.62 ± 0.03</td>
<td>110.7 ± 2.8</td>
</tr>
<tr>
<td>MasKO -</td>
<td>29.3 ± 0.7*</td>
<td>0.48 ± 0.004</td>
<td>1.63 ± 0.03</td>
<td>102.6 ± 3.4</td>
</tr>
<tr>
<td>+</td>
<td>28.3 ± 0.5</td>
<td>0.47 ± 0.008</td>
<td>1.67 ± 0.04</td>
<td>112.0 ± 5.9</td>
</tr>
<tr>
<td>DKO -</td>
<td>28.2 ± 0.5</td>
<td>0.46 ± 0.007</td>
<td>1.61 ± 0.03</td>
<td>109.8 ± 5.9</td>
</tr>
<tr>
<td>+</td>
<td>28.7 ± 0.4</td>
<td>0.45 ± 0.011</td>
<td>1.61 ± 0.03</td>
<td>124.8 ± 2.1†</td>
</tr>
</tbody>
</table>

*p<0.05 vs. WT-sham. †p<0.05 vs. DKO-sham.

**Table S2.** Body weight, brain weight and systolic blood pressure according to Ang-(1-7) treatment.

<table>
<thead>
<tr>
<th>Ang-(1-7) (0.5 mg/kg/day)</th>
<th>Body weight (g)</th>
<th>Brain weight (g)</th>
<th>Brain/Body weight ratio(%)</th>
<th>Systolic blood pressure(mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT -</td>
<td>26.7 ± 1.2</td>
<td>0.43 ± 0.009</td>
<td>1.64 ± 0.06</td>
<td>113.8 ± 7.2</td>
</tr>
<tr>
<td>+</td>
<td>26.8 ± 0.8</td>
<td>0.42 ± 0.005</td>
<td>1.60 ± 0.05</td>
<td>121.0 ± 5.1</td>
</tr>
<tr>
<td>MasKO -</td>
<td>28.3 ± 0.7</td>
<td>0.44 ± 0.011</td>
<td>1.57 ± 0.04</td>
<td>107.8 ± 5.2</td>
</tr>
<tr>
<td>+</td>
<td>28.9 ± 0.6</td>
<td>0.46 ± 0.005</td>
<td>1.60 ± 0.03</td>
<td>115.1 ± 2.5</td>
</tr>
<tr>
<td>AT2KO -</td>
<td>27.1 ± 1.4</td>
<td>0.43 ± 0.009</td>
<td>1.61 ± 0.06</td>
<td>103.6 ± 3.8</td>
</tr>
<tr>
<td>+</td>
<td>26.5 ± 1.0</td>
<td>0.42 ± 0.010</td>
<td>1.61 ± 0.04</td>
<td>97.0 ± 4.7</td>
</tr>
<tr>
<td>DKO -</td>
<td>28.4 ± 0.5</td>
<td>0.45 ± 0.007</td>
<td>1.61 ± 0.03</td>
<td>107.5 ± 1.9</td>
</tr>
<tr>
<td>+</td>
<td>28.1 ± 0.5</td>
<td>0.45 ± 0.002</td>
<td>1.61 ± 0.03</td>
<td>104.8 ± 3.1</td>
</tr>
</tbody>
</table>
Figure S1.

**Time-course analysis of CBF changes after BCAS surgery.**  **A,** The percentage to the baseline CBF at the point of 0, 1, 2, 4 and 6 weeks after the BCAS surgery is indicated (n=6-11 for each group). *p<0.01 vs. WT and MasKO.**  **B,** The area under the curve in the time-course graph is calculated with trapezoidal method in each group. WT, wild type mice; MasKO; Mas receptor knockout mice; AT\textsubscript{2}KO; AT\textsubscript{2} receptor knockout mice; DKO, Mas/AT\textsubscript{2} receptor double-knockout mice.
Severity of the white matter lesion. The demyelinating changes in the white matter lesion are determined with Klu¨ver-Barrera staining. The severity of the WM lesions was graded as normal (grade 0), disarrangement of the nerve fibers (grade 1), the formation of marked vacuoles (grade 2), and the disappearance of myelinated fibers (grade 3). A, Representative brain images with Kluver-Barrera staining in the corpus callosum level. B, Averaged severity scores are indicated. The score is significantly higher in BCAS.
treated groups compared to the sham groups in each group, but there is no significant inter-group difference (n=3-6 for each group). WT, wild type mice; MasKO; Mas receptor knockout mice; AT2KO; AT2 receptor knockout mice; DKO, Mas/AT2 receptor double-knockout mice.